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Abstract
Background: Hereditary Spastic Paraplegias (HSP) are characterized by progressive spasticity and weakness of the
lower limbs. At least 45 loci have been identified in families with autosomal dominant (AD), autosomal recessive
(AR), or X-linked hereditary patterns. Mutations in the SPAST (SPG4) and ATL1 (SPG3A) genes would account for
about 50% of the ADHSP cases.
Methods: We defined the SPAST and ATL1 mutational spectrum in a total of 370 unrelated HSP index cases from
Spain (83% with a pure phenotype).
Results: We found 50 SPAST mutations (including two large deletions) in 54 patients and 7 ATL1 mutations in 11
patients. A total of 33 of the SPAST and 3 of the ATL1 were new mutations. A total of 141 (31%) were familial cases,
and we found a higher frequency of mutation carriers among these compared to apparently sporadic cases (38%
vs. 5%). Five of the SPAST mutations were predicted to affect the pre-mRNA splicing, and in 4 of them we
demonstrated this effect at the cDNA level. In addition to large deletions, splicing, frameshifting, and missense
mutations, we also found a nucleotide change in the stop codon that would result in a larger ORF.
Conclusions: In a large cohort of Spanish patients with spastic paraplegia, SPAST and ATL1 mutations were found
in 15% of the cases. These mutations were more frequent in familial cases (compared to sporadic), and were
associated with heterogeneous clinical manifestations.
Background
The hereditary spastic paraplegias (HSP) are character-
ized by progressive spasticity and weakness of the lower
limbs due to axonal degeneration in the pyramidal tract.
The disease is classified as “pure” when spasticity is the
only clinical finding, and as “complicated” when other
clinical features (dementia, cerebellar ataxia, epilepsy,
peripheral neuropathy) are also present [1]. HSP is fre-
quently familial and at least 45 loci have been identified
in families with autosomal dominant (AD), autosomal
recessive (AR), or X-linked inheritance [2-4]. This
genetic heterogeneity partly explains the differences in
disease severity, age at onset, rate of progression, and
degree of disability between families. However, intrafa-
milial heterogeneity is also frequent.
SPG4 (OMIM#604277) is the most common form of
HSP, accounting for approximately 40% of the familial
and 6-15% of the sporadic cases. The SPAST/SPG4 gene
encodes spastin, a member of the AAA (ATPase asso-
ciated with various cellular activities) family of proteins,
implicated in the remodeling of protein complexes upon
ATP hydrolysis and the coordination of axonal microtu-
bule interactions with the tubular endoplasmic reticu-
lum network [5,6]. To date, >240 SPAST mutations have
been reported (http://www.hgmd.cf.ac.uk/ac/index.php;
date of consultation August 2, 2010), mainly in patients
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single-nucleotide changes or small deletions/insertions,
but large deletions and duplications have also been
reported [13-16]. This suggested that both, haploinsuffi-
ciency and “toxic” gain of function could explain the
pathogenic mechanism of SPAST mutations [5,17-19].
SPG3A (OMIM#606439) is the second most frequent
form of ADHSP. The ATL1/SPG3A gene encodes atlas-
tin, a protein localized in the endoplasmic reticulum
and the Golgi and implicated in vesicle trafficking and
neurite outgrowth [20,21]. To date, >25 ATL1 mutations
have been reported (http://www.hgmd.cf.ac.uk/ac/index.
php; date of consultation August 2, 2010), mainly mis-
sense changes that supported a gain of function patho-
genic mechanism. ATL1 mutations accounted for
approximately 10% of the ADHSP families, and have
been mainly found in pure HSP [22,23]. ATL1 muta-
tions are also frequent in early onset (childhood or ado-
lescence) cases [24-26].
This is the first report of the mutational spectrum of
the SPAST and ATL1 genes in a large cohort of unre-
lated HSP patients from Spain. Few studies on cohorts
>200 patients have been published, and the parallel
screening of both genes was rarely reported.
Methods
Patients
This study was approved by the Ethical Committee of
Hospital Universitario Central Asturias (HUCA), and all
the participants (patients and controls) signed an informed
consent. A total of 370 non-related patients (index cases)
were recruited through the Neurology Departments of
several Hospitals from Spain. HSP was diagnosed by quali-
fied neurologists on the basis of Harding’s criteria. Based
on the clinical, radiological, and biochemical findings,
cases with diseases that mimicked spastic paraplegia were
excluded [27]. A total of 141 patients (38%) had a family
history of HSP with a dominant inheritance pattern, and
were thus classified as ADHSP cases. The absence of
family history of the disease was established in 229
patients (62%) after interview on their first and second
degree relatives. These cases were classified as “apparently”
sporadic or with an uncertain inheritance pattern. In 177
of these the two parents were alive and did not have symp-
toms consistent with HSP, while in 52 the inheritance pat-
tern could not be established because no clinical data were
available from relatives.
SPAST and ATL1 sequencing
DNA was obtained from blood leukocytes and the 17
coding exons of SPAST (plus at least 50 bp of the flank-
ing intronic sequences) were polymerase chain reaction
(PCR) amplified (Additional file 1, Table S1). PCR frag-
ments were purified and the two strands were sequenced
using Big Dye chemistry in an ABI3130 system (Applied
Biosystems, Ca, USA). These sequences were compared
with the SPAST reference sequence (ENSG00000021574
for the genomic; ENST00000315285 for the transcript;
http://www.ensembl.org). In patients who were negative
for SPAST mutations and had ADHSP (n = 88) or
patients without a family history of HSP and onset age
≤20 years (n = 99), we amplified and sequenced the 13
coding exons of ATL1 (reference sequences
ENSG00000198513 for the genomic, and
ENST00000358385 for the transcript; http://www.
ensembl.org). All the DNA sequence variants were
named following the guidelines of the Human Genome
Variation Society (http://www.hgvs.org/mutnomen).
Controls screening
All the new putative mutations (not previously reported
as SPAST or ATL1 mutations or polymorphisms) were
screened in 400 controls. These were healthy individuals
aged 21-65 years recruited through the Blood Bank of
HUCA. The new nucleotide changes were genotyped
through PCR-RFLP, single strand conformation analysis
(SSCA), or denaturing high performance liquid chroma-
tography (DHPLC), as reported [28]. Each PCR fragment
containing a putative mutation gave a characteristic
RFLP, SSCA or DHPLC pattern, and we could thus
determine its presence/absence in the controls. When a
new nucleotide change was not found among the 400
controls we determined, when it was possible, the car-
rier status of all the available affected relatives to con-
firm the segregation of the mutation with the disease.
MLPA analysis
The multiplex ligation dependent probe amplification
(MLPA) assay with the Salsa Kit P165 HPA (MRC Hol-
land, Amsterdam) was used to determine the existence
of genome copy number aberrations in the SPAST and
ATL1 genes in ADHSP patients who were negative for
sequencing mutations [13]. To investigate the conse-
quences of large SPAST deletions at the transcript level,
we isolated the mRNA from leukocytes in 10 ml of
blood (Trizol reagent, Invitrogen, Carlsbad, CA, USA)
and synthesised the cDNA (Quantitec Reverse Tran-
s c r i p c i o nk i t ,Q u i a g e n ,H i l d e n ,G e r m a n y ) .T h ec D N A
was amplified with primers that matched exons flanking
the deletion (conditions available upon request), and the
PCR products were purified and sequenced.
Analysis of SPAST transcripts
To determine the effect of some SPAST mutations on
mRNA transcripts, the cDNA synthesised from leukocytes
was amplified with primers that matched the exons flank-
ing the mutation (additional file 1, Table S2), and the PCR
fragments were purified from agarose gels and sequenced.
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The analysis of variance (SPSS 17.0 software) was used
to compare the mean onset age and disease duration
between patients with mutations in SPAST and ATL1
and patients without mutations.
Results
Patients characteristics
We studied a total of 370 unrelated HSP index cases,
with a mean onset age of 28 (± 21) years (range 1-77
years), and a mean disease duration of 17 (± 15) years.
A total of 321 patients (87%) had a pure HSP, while 49
(13%) were complicated cases with peripheral neuropa-
thy (the most frequent finding), cerebellar or cerebral
atrophy, mental retardation, nystagmus, or dysarthia.
A total of 44 of the 141 patients (31%) with ADHSP had
a SPAST mutation, and 10 mutations were found among
the 229 (5%) cases apparently sporadic or with an uncer-
tain inheritance pattern. However, in three of these
patients the mutation (p.Leu426Val, p.Lys503insArg, and
p.Met390Val) was de novo because none of the two parents
was mutation carrier (the paternity was confirmed). We
found 10 ATL1 mutation carriers among 88 ADHSP cases
(11%), and the only apparently sporadic proband had a de
novo mutation (p.Gln154Glu) (Additional file 2, Figure S1).
SPAST mutations
We found 48 SPAST mutations in 52 patients (Table 1).
These were missense changes in amino acids conserved
between species (n = 22), nonsense mutations (n = 7),
small frameshifting insertions/deletions (n = 13), nucleo-
tide changes in the intronic splicing consensus sequence
(n = 5), and a sense mutation in the stop codon (Figure
1). A total of 15 mutations had been previously
reported, while 33 (69%) were novel.
SPAST missense mutations out of the AAA domain
M o s to ft h em i s s e n s em u t a t i o n sw e r ei nt h eA A A
domain. Two novel missense changes (p. Pro293Leu,
and p. Asp613Ala) were outside of the AAA domain,
w h e r em i s s e n s em u t a t i o n sh a v eb e e nr a r e l yf o u n d .T h e
two amino acids were evolutionary conserved. The p.
Pro293Leu proband was a 51-year-old man with pro-
gressive gait disorder starting at the age of 31, who has
been confined to a wheelchair due to his spasticity (pure
form) for the last two years. His 46-year-old sister, and
one of his daughters (18 years old) also carried this
mutation. They both presented brisk reflexes and
Babinski’s sign, but no spasticity and an almost normal
gait. The p.Asp613Ala was found in a 45 years old man
with a pure phenotype affecting only the lower limbs
and the first symptoms at the age of 36 years. He did
not report a family history of the disease, although no
relatives were studied.
We also found a new SPAST missense variant (p.
Ile328Leu) in a 15 years old male with complicated
spastic paraplegia starting at the age of 18 months. This
putative mutation was also found in his father’sg r a n d -
mother (asymptomatic), but the proband’s father was
not available for study. Although this variant was not
found among the controls and involved a conserved
amino acid, a bioinformatics analysis (SIFT v2. program,
S o r t i n gI n t o l e r a n tF r o mT o l e r a n t ;h t t p : / / s i f t . j c v i . o r g / )
indicated a non significant change in the protein func-
tion, and was thus classified as a change of uncertain
pathogenic effect.
G (exon 3) affected
splicing",1,0,1,0,0pc,0pc,0pc,0pc>SPAST c.583C>G (exon 3)
affected splicing
The c.583C>G (p.Leu195Val) was found in a 19 years
old male with an onset at the age of 2 years and a phe-
notype complicated with neuropathy. He was from a
family with ADSPH in which we confirmed the segrega-
tion of the disease with this mutation. This has been
previously reported as a missense mutation, and the
bioinformatic analysis (SIFT v2. program) indicated that
this change would affect the protein function. However,
the c.583C>G was four nucleotides from the 3’ end of
exon 3, and was also predicted to reduce the score of
the splicing consensus site (Human Splicing Finder v.
2.4; http://www.umd.be/SSF). This mutation could thus
result in an aberrant mRNA sequence. To confirm this,
we isolated the mRNA from the patient’s blood leuko-
cytes and amplified the SPAST cDNA with primers for
exons 2 and 7. The last 4 nucleotides of exon 3 were
missed in the transcript, that would thus be translated
into an aberrant protein (Figure 2A).
SPAST sense mutation
We found a novel mutation in the SPAST stop codon,
c.1849T>G (p.X617Glu) in two non related patients with-
out known affected relatives. The mutated transcript was
predicted to be translated into a 46 amino acids longer
protein. To determine the stability of the mRNA contain-
ing this mutation, we synthesized the cDNA from RNA
obtained from leukocytes of one of the patients and
amplified and sequenced a PCR-fragment generated with
primers that matched exons 11 and the 3’ untranslated
region (UTR). The two alleles gave equally intense
sequence electropherogram peaks, suggesting that
c.1849G did not increase the mRNA decay and was likely
translated into a mutated protein (Figure 2B).
SPAST mutations affecting splicing
In addition to the above described c.583C>G in exon 3
of SPAST, we found five changes in intron splicing con-
sensus nucleotides. The in silico analysis (Splice Site
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Case Onset age (Years) Phenotype* GENE EXÓN Mutation Protein change Reference
193 60 Pure-UHSP SPAST 1 c.349C->T p.Arg117X This study
69 45 Pure-SHSP SPAST 2 c.469delG p.Glu157f sX159 This study
81 35 Pure-SHSP SPAST 3 c.577C>T p.Gln193X [7]
138 2 Complicated-ADHSP SPAST 3 c.583C->G p.Leu195Val [10]
166 43 Pure-ADHSP SPAST 5 C.782C>G p.Ser261X [7]
197 53 Pure-ADHSP SPAST 5 c.857-859delCTA p.Pro286-Thr287delinsP This study
257 23 Pure-ADHSP SPAST 5 c.806c->G Tyr269X [7]
300 8 Pure-ADHSP SPAST 5 c.746C>G p.Ser249X [8]
174 1 Pure-ADHSP SPAST 6 c.879delG p. Pro293fsX314 This study
205 20 Pure-ADHSP SPAST 6 .936-37insA pLys.312fsX318 This study
206 30 Pure- UHSP SPAST 6 c.977-978insA p.Asn326fsX331 This study
335 32 Pure- SHSP SPAST 6 c.878C>T p.Pro293Leu This study
13 40 Pure-ADHSP SPAST 7 c.1040A>C p.Gln347His This study
130 0 Complicated-ADHSP SPAST 7 c.1082C>T p.Pro361Leu [41]
133 35 Pure-ADHSP SPAST 7 c.1054C>T p.Gln352X This study
351 Pure-ADHSP SPAST 7 c. 1091-1098delGGCCTGAG p.Arg364fsX392 This study
47 66 Pure-ADHSP SPAST 8 c.1139T>A p.Leu380His [15]
111 49 Pure-ADHSP SPAST 8 c.1133T->G p.Leu378Arg This study
180 54 Pure-ADHSP SPAST 8 c.1172T>C p.Leu391Pro [42]
273 1 Complicated-SHSP SPAST 8 c.1168A->G p.Met390Val [43]
7 44 Pure-ADHSP SPAST 9 c.1215-1219delTATAA p. Asn405fsX441 [7]
22 42 Pure-ADHSP SPAST 9 c.1174-1180delGCTAAG p.Ala392fsX405 This study
23 35 Pure-ADHSP SPAST 9 c.1226G>A p.Ala409Thr This study
32 35 Pure-ADHSP SPAST 9 c.1177-1180delAAAGCAGTA GCT p.Lys393-Ala396del This study
52 45 Pure-ADHSP SPAST 9 c.1210-1212delTTT p.Phe404del [44]
80 38 Pure-ADHSP SPAST 9 c.1210-1212delTTT p.Phe404del [44]
98 29 Pure-ADHSP SPAST 9 c.1192-93delGA/insT Glu398fsX406 This study
179 10 Pure-ADHSP SPAST 9 c.1192-93delGA/insT Glu398fsX406 This study
363 2 Pure_ADHSP SPAST 9 C.1128A>C p.Ser410Arg This study
135 47 Pure-ADHSP SPAST 10 c.1306T>C p.Ser436Pro This study
170 3 Complicated-SHSP SPAST 10 c.1276 C>G p.Leu426Val [7]
373 10 Pure-ADHSP SPAST 10 c. 1321G->A p.Asp441Asn This study
50 2 Pure-ADHSP SPAST 11 c.1387A>G p.Thr463Ala This study
200 35 Pure-ADHSP SPAST 11 c.1378c>A p.Arg460Ser [45]
308 30 Pure -ADHSP SPAST IVS11 c.1414-2A>C Exon 12 skipping This study
322 30 Pure_ADHSP SPAST IVS11 c.1414-1G>C Exon 12 skipping This study
86 40 Pure- ADHSP SPAST 12 c.1439-1145delTACTTGT/insC p.Val480fs This study
118 61 Pure-ADHSP SPAST 12 c.1466C-> T p.Pro489Leu [46]
177 20 Pure-ADHSP SPAST 12 c.1492A<G p.Arg498Gly This study
352 Pure-ADHSP SPAST 12 c.1474C>T p.Leu492Phe This study
145 16 Pure-ADHSP SPAST IVS12 c1494-2A>G presumed missplicing This study
178 1 Pure-SHSP SPAST 13 c.1507-1508insGGC p.Lys503insArg This study
334 32 Pure-ADHSP SPAST 13 c.1540A>G p.Arg503Trp [11]
358 30 Pure-ADHSP SPAST 14 c.1540A>G p.Arg514Gly [12]
253 18 Pure-ADHSP SPAST 15 c.1684C>T p.Arg562X [7]
261 50 Pure-ADHSP SPAST IVS15 c.1687+1G/A Ex15 skipping [7]
62 40 Pure-ADHSP SPAST IVS15 c.1687+1G/T Ex15 skipping This study
103 40 Pure-ADHSP SPAST 17 c.1793T-> C p.Ile580Thr This study
112 56 Pure-ADHSP SPAST 17 C.1739T-> C p.Ile580Thr This study
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seq_tools/splice.html) indicated that the five changes
would affect the pre-mRNA splicing. We could synthe-
size the cDNA from four of the patients, that was ampli-
fied with primers that matched exons 7 and 17, and
exons 11 and 17. In all these cases two PCR-fragments
were amplified, and the longer fragment corresponded
to the wild type transcript while the shorter resulted
from an exon skipping. In this way, we confirmed the
existence of defective transcripts (Figure 2C).
Large SPAST deletions
We performed MLPA analysis in the 77 ADHSP cases who
were negative for ATL1 and SPAST sequencing mutations.
Two patients (2.5%) showed a significantly reduced ampli-
fication signal for exons 10-16, or exons 6-7 of SPAST.I n
the patient with a putative deletion of exons 10-16 we
amplified the cDNA with primers that matched exons 9
and 17, and confirmed the skipping of exons 10-16 (Figure
2D). In this pedigree, the age at onset (third decade) was
similar in the three affected members who were studied,
and the oldest patient (an 81-year-old man) had been con-
fined to a wheelchair for the previous five years.
ATL1 mutations
The ATL1 exons were sequenced in a total 88 patients
with ADHSP and in 99 patients without a family history
of HSP and an onset age ≤20 years. We found seven
mutations and a variant with uncertain pathogenic effect
in 11 patients (Table 2). Three were novel missense
changes (p.His256Asp, p.Gln154Glu, and p.Phe413Val),
while 5 had been reported. The p.Arg239Cys was a
recurrent mutation found in 3 non related patients.
Mutations p.Gln154Glu, (c.460 C>G), p. His256Asp
(c.766C>A), and p.Phe413Val (c.1237T>G) are located in
the guanilate binding protein domains. The p.Gln154Glu
mutation was found in a patient with a pure phenotype
and onset of symptoms in childhood. His son showed gait
problems at the age of two years. The p.His256Asp patient
was a 45 years old woman with the onset of symptoms at
the age of 3 years and a progressive spastic paraplegia
(Additional file 2, Figure S1). In her family, we identified
mutation carriers who were asymptomatic at ages of 60
and 63 years, and this could thus be classified as a variant
with uncertain pathogenic effect. Mutation p.Phe413Val
was found in a patient with an onset age of 6 years and a
complicated phenotype (neuropathy). Her mother was
affected, but she was death and we could not confirm
whether carried the mutation. None of the 77 ADHSP
patients studied through MLPA showed evidence for large
ATL1 deletions.
SPAST and ATL1 polymorphisms
We found several polymorphisms in the two genes
(Additional file 1, Table S3). All the new polymorphisms
were intronic, or exonic silent amino acid changes with
one exception: c.844 T>A in exon 5 of SPAST (p.
Ser282Thr). This missense change affected an amino
conserved between species and was not found in any of
the 400 controls. Although it could be considered a
putative mutation, was in a patient with the p.Ser261X
mutation (located also in exon 5). Segregation analysis
to determine whether the two nucleotide changes were
in different chromosomes was not possible. However,
the electrophoretic pattern of bands after double restric-
tion enzyme digestion (MnlI + MboI) of the exon 5 frag-
ment indicated that the mutation was in cis with the
c.844 A allele (data not shown). This suggested that this
was likely a rare variant, rather than an HSP mutation.
Two missense polymorphisms that have been proposed
as modifiers of the clinical phenotype (p.Ser44Leu and
p.Pro45Leu) were not found in our patients [29].
Genotype-phenotype correlation
The phenotype associated with SPAST and ATL1 muta-
tions was pure in 48 (87%) and 10 (90%) of the index
patients, respectively. We analysed all the available rela-
tives of the 63 index cases with mutations, and identified a
total of 54 SPAST and 15 ATL1 mutation carriers. A total
of 13 mutation carriers (10 for SPAST and 3 for ATL1
gene) were asymptomatic at the time of our analysis. The
mean onset age of the disease (index cases and relatives)
was 34.5 (± 17.72) years for SPAST mutation carriers, and
7.67 (± 5.9 years) for ATL1 mutation carriers (p < 0.001).
A difference was also observed between ATL1 mutation
carriers and patients without SPAST/ATL1 mutations
Table 1 Mutations identied in the SPAST gene in the Spanish HSP cohort (Continued)
212 35 Pure-ADHSP SPAST 17 c.1849T-> G p.X617Glu This study
286 54 Complicated-UHSP SPAST 17 c.1849T-> G p.X617Glu This study
310 36 Pure- UHSP SPAST 17 C.1838A-> C p.Asp613Ala This study
EXON DELETIONS
199 20 Pure-ADHSP SPAST - EX10-16 deletion [14]
225 14 Pure-ADHSP SPAST - Ex 6-7 deletion This study
* ADHSP- Autosomal dominant spastic paraplegia; SHSP: apparently sporadic spastic paraplegia (including siblings with healthy parents); UHSP: Unkown familial
history spastic paraplegia
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tion of symptoms at the time of examination did not differ
between patients with SPAST (14.5 ± 11.1) and ATL1
(18.78 ± 15.057) mutations. No difference in disease dura-
tion was observed between SPAST or ATL1 mutation car-
riers and patients without mutations.
Discussion
SPAST mutations (including large gene deletions) were
found in 15% (54/370) of the patients, but this frequency
increased to 31% (44/141) among patients with ADHSP.
Most of the SPAST mutations were novel, and this was in
agreement with previous reports that described a high
rate of private mutations in this gene [30,10,15]. We
found an ATL1 mutation in 6% of the patients studied
for this gene, but this frequency could be underestimated
because we did not include ADHSP patients with a
SPAST mutation or patients with sporadic/uncertain
HSP and an onset age >20 years. However, we think that
the ATL1 mutation rate should be right because double
mutated patients (SPAST + ATL1) have not been
reported, and ATL1 mutations were rare among non-
ADHSP patients with an onset age >20 years [22,25,26].
Considering the ADHSP cases, the mutational screening
of SPAST and ATL1 identified a total of 54 mutation car-
riers, a frequency (38%) within the range reported in other
populations [10,12,31,32]. Also in agreement with previous
reports, the frequency of SPAST and ATL1 mutation car-
riers was much lower among patients with sporadic/
uncertain HSP [12]. Four of the sporadic cases had a de
novo mutation. A high rate of de novo mutational events
for SPAST and ATL1 has been previously described, indi-
cating that sporadic cases should also be screened for
mutations in these genes after exclusion of other major
neurological causes of spasticity [15,23,33-35].
SPAST mutations are mostly restricted to the AAA
protein domain. It is thus remarkable that three of the
missense mutations in our patients were out of this
domain (p.Leu195Val, p.Pro293Leu, and p.Asp613Ala).
I nt h ec a s eo fATL1 all the mutations were missense
changes in the GTPase and transmembrane domains of
atlastin, and would disrupt the normal protein folding
and oligomerization [20,21]. The SPAST c.C583G variant
was previously reported as a missense mutation (p.
Leu195Val) [10]. However, this change was within the
consensus splicing sequence of exon 3 and we confirmed
its effect on pre-RNA splicing. Nucleotide changes in the
last nucleotides of exons could result in both, normal
and splicing defective transcripts [36-38]. Although we
found an aberrant transcript we could not define whether
the c.583 G resulted also in normal transcripts.
In the SPAST gene we also found one mutation in the
stop codon (c.1849T>G; X617Glu), that would result in
the translation of 46 amino acid beyond the stop codon.
To our knowledge, this is the first sense mutation reported
in this gene. The abolishment of a stop codon and the
appearance of a longer ORF has been found in other her-
editary diseases, such as the British Familial Dementia
caused by a sense mutation in the ITM2B gene [39].
We performed MLPA analysis in 78 patients with
ADHSP and we found two large deletions in the SPAST
gene, which accounts for 2.5% of patients. In a recent
Figure 1 Schematic diagram of SPAST and ATL1 domains showing the location of the mutations. The one letter code was used to
identify the amino acid changes. Novel mutations are in bold.
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Page 6 of 9Figure 2 A) The cDNA from patient 138 (carrier of c.583C>G in exon 3 of SPAST) was synthesised from leukocytes mRNA.T h e
sequencing of the fragment amplified with primers that matched exons 2 and 7 showed the deletion of the last 4 nucleotides of exon 3. B)
The cDNA from patient 212 (X617Glu) was amplified with primers for exons 11 and 17 of SPAST, and the sequence showed similar
electropherogram peaks for the two alleles. C) The cDNA of patient 322 was amplified with primers for exons 7 and 17 of SPAST, and the
sequence showed the effect on splicing of the c.1414-1G>C mutation. D) MLPA of the SPAST gene in patient 199, showing the exons 10-16
deletion. The cDNA was amplified with primers that matched exons 9 and 17, and two PCR fragments were obtained. Sequencing of the smaller
fragment confirmed the absence of exons 10 to 16. P = patient (cDNA); M = Patient’s mother’s (cDNA); C = Control (cDNA); G = Genomic DNA
Table 2 Mutations in the ATL1 gene
Case onset age (Years) Phenotype/Inheritance GEN Exon Mutation Protein Reference
57.1 1 Pure- SHSP ATL1 4 c.460 C>G p.Gln154Glu This study
97 8 Pure-ADHSP ATL1 7 c.715C>T p.Arg239Cys [47]
102 4 Pure-ADHSP ATL1 7 c.715C>T p.Arg239Cys [47]
220 3 Pure-ADHSP ATL1 7 c.715C>T p.Arg239Cys [47]
279 5 Pure-ADHSP ATL1 7 c.715C>T p.Arg239Cys [47]
64 10 Pure-ADHSP ATL1 8 c.757 G>A p.Val253Ile [25]
159 5 Pure-ADHSP ATL1 12 c.1483c>T p.Arg495Trp [25]
110 17 Pure-ADHSP ATL1 12 c.1319A->C p.Asn440Thr [25]
232 6 Pure-ADHSP ATL1 12 c.1237T->G p.Phe413Val This study
233 16 Complicated-ADHSP ATL1 12 c.1243 C->T p.Arg415Trp [40]
Álvarez et al. BMC Neurology 2010, 10:89
http://www.biomedcentral.com/1471-2377/10/89
Page 7 of 9work Shoukier et al. reported a similar frequency for this
type of mutation [12]. However, previous studies reported
a much higher frequency (18-23%) [13,15]. Additional stu-
dies are thus necessary to define the frequency of large
deletions/duplications in the aetiology of HSP.
Finaly, SPAST and ATL1 mutations have been asso-
ciated with variable penetrance, leading to heterogeneous
HSP phenotypes in terms of onset age and clinical symp-
toms (pure vs. complicated) [40,15]. This heterogeneity
could be partly explained by different mutated genes. As
discussed above, we observed a significantly higher fre-
quency of familial dominant HSP among ATL1 patients,
compared to SPAST mutation carriers, and pure HSP
was also more frequent among the patients with ATL1
mutations. However, phenotypic variability was also com-
mon among mutation carriers from the same family.
Conclusions
In conclusion, we reported the mutational spectrum of
the SPAST and ATL1 genes in a large cohort of Spanish
patients with spastic paraplegia. We found a mutation in
15% of the cases, and a frequency of mutation carriers
significantly higher among ADHSP compared to spora-
dic cases. Thus, the genetic screening should be more
relevant in patients (pure and complicated phenotypes)
w i t haf a m i l yh i s t o r yo ft h ed i s e a s e .H o w e v e r ,t h ef a c t
that a significant number of apparently sporadic cases
had a mutation suggested that these patients should not
be excluded from the genetic study. The mutational
report could be of limited value to predict the pheno-
type associated to these mutations, as demonstrated by
the heterogeneous behavior of most of the mutations.
Note
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Catalina-Alvarez, José L. Muñoz-Blanco, Miguel Fernán-
dez-Burriel, Juan B. Espinal, Mariano Aparicio- Blanco,
Jon Infante, María Vázquez-Espinar, Elena Maside
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